These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6155298)

  • 1. The effect of aprotinin on the absorption of subcutaneously injected regular insulin in normal subjects.
    Berger M; Cüppers HJ; Halban PA; Offord RE
    Diabetes; 1980 Jan; 29(1):81-3. PubMed ID: 6155298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations.
    Berger M; Cüppers HJ; Hegner H; Jörgens V; Berchtold P
    Diabetes Care; 1982; 5(2):77-91. PubMed ID: 6765510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of aprotinin on regional absorption of soluble human insulin.
    Owens DR; Vora JP; Birtwell J; Luzio S; Hayes TM
    Br J Clin Pharmacol; 1988 Apr; 25(4):453-6. PubMed ID: 2454647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous aprotinin causes local hyperaemia. A possible mechanism by which aprotinin improves control in some diabetic patients.
    Williams G; Pickup JC; Bowcock S; Cooke E; Keen H
    Diabetologia; 1983 Feb; 24(2):91-4. PubMed ID: 6188643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of aprotinin on insulin absorption and subcutaneous blood flow in type 1 (insulin-dependent) diabetes.
    Linde B; Gunnarsson R
    Diabetologia; 1985 Sep; 28(9):645-8. PubMed ID: 2415419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical approach to subcutaneous dosage forms of insulin.
    Hori R; Komada F; Okumura K
    J Pharm Sci; 1983 Apr; 72(4):435-9. PubMed ID: 6191020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twenty-four hour blood glucose profiles during insulin and insulin plus aprotinin subcutaneous administration in type I diabetes.
    Lunetta M; Napoli E; Sudano L; Leonardi R; Mughini L
    Horm Metab Res; 1986 Mar; 18(3):182-4. PubMed ID: 2422103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aprotinin induced lipohypertrophy and glomerulonephritis in an insulin dependent diabetic.
    Dandona P; Mier A; Boag F; Chappell M; Beckett AG
    Diabetes Res; 1985 Jul; 2(4):213-6. PubMed ID: 2417774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Studies on the absorption kinetics of subcutaneously administered insulin].
    Misawa K
    Hokkaido Igaku Zasshi; 1989 Nov; 64(6):792-812. PubMed ID: 2691384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous use of regular human insulin (Novo): pharmacokinetics and continuous insulin infusion therapy.
    Sonnenberg GE; Kemmer FW; Cüppers HJ; Berger M
    Diabetes Care; 1983; 6 Suppl 1():35-9. PubMed ID: 6343035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin.
    Morishita M; Morishita I; Takayama K; Machida Y; Nagai T
    Biol Pharm Bull; 1993 Jan; 16(1):68-72. PubMed ID: 7690292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aprotinin on insulin sensitivity in non-insulin-dependent diabetes mellitus.
    Laurenti O; Piccoli A; Bravi C; Cassone-Faldetta M; Bellini C; Leoni L; Ferri C; De Mattia G
    Diabet Med; 1996 Jul; 13(7):642-5. PubMed ID: 8840098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous degradation of insulin.
    Stevenson RW
    Diabetologia; 1982 Mar; 22(3):221-3. PubMed ID: 6176491
    [No Abstract]   [Full Text] [Related]  

  • 14. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer.
    Heinemann L; Klappoth W; Rave K; Hompesch B; Linkeschowa R; Heise T
    Diabetes Care; 2000 Sep; 23(9):1343-7. PubMed ID: 10977030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: Investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats.
    Cilek A; Celebi N; Tirnaksiz F; Tay A
    Int J Pharm; 2005 Jul; 298(1):176-85. PubMed ID: 15950411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site dependence of absorption-promoting actions of laureth-9, Na salicylate, Na2EDTA, and aprotinin on rectal, nasal, and buccal insulin delivery.
    Aungst BJ; Rogers NJ
    Pharm Res; 1988 May; 5(5):305-8. PubMed ID: 2469079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors.
    Hildebrandt P
    Dan Med Bull; 1991 Aug; 38(4):337-46. PubMed ID: 1914533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects.
    Bantle JP; Neal L; Frankamp LM
    Diabetes Care; 1993 Dec; 16(12):1592-7. PubMed ID: 8299455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin absorption accelerated by alpha-adrenergic blockade at injection site.
    Menon RK; Gaylarde PM; Hyden AM; Grace AA; Dandona P
    Diabetes Care; 1987; 10(4):470-2. PubMed ID: 3304897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorption rates of subcutaneously injected insulin in the dog as calculated from the plasma insulin levels by means of a simple mathematical model.
    Fischer U; Freyse EJ; Jutzi E; Besch W; Raschke M; Höfer S; Albrecht G
    Diabetologia; 1983 Mar; 24(3):196-201. PubMed ID: 6341148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.